Mutation, gene amplification, and gene fusion of KAT6A and/or KAT6B are associated with oncogenesis (7, 8, 9), and cancer cell lines that overexpress KAT6A are dependent on this enzyme, strongly suggesting that it is a therapeutic vulnerability (6). The gene discussed is KAT6A; the disease is cancer.